The functional assessment of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers

Quality of Life Research

Volumn 13, Issue 1, 2004, Pages 137-154

  Bacik, J ^a   Mazumdar, M ^a   Murphy, B A ^c   Fairclough, D L ^d   Eremenco, S ^e   Mariani, T ^a   Motzer, R J ^a,b   Cella, D ^e,f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biologic response modifiers; FACT BRM; FACT G; Quality of life assessment; Renal cell carcinoma

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; INTERFERON; ISOTRETINOIN; RETINOID;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANEMIA; APPETITE DISORDER; ARTHRALGIA; CANCER PATIENT; CANCER THERAPY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRY EYE; EYE TOXICITY; FATIGUE; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEMORY DISORDER; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; OUTCOMES RESEARCH; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SWEATING; SYMPTOM; THROMBOCYTOPENIA; TOXICITY; VALIDATION PROCESS; VOMITING; WELLBEING; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2A; MALE; QUALITY OF LIFE; QUESTIONNAIRES; SELF ASSESSMENT (PSYCHOLOGY); SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 1542285315     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:QURE.0000015297.91158.01     Document Type: Conference Paper

References (24)

1. Fairclough DL. Quality of life, cancer investigation, and clinical practice. Cancer Invest 1998; 16: 478-484.
2. Cella DF. The Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Version 4, 1997.
3. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
4. Jonasch E, Haluska FG. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. The Oncologist 2001; 6: 34-55.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417.
6. Chapman PB, Parkinson DR, Kirkwood JM. Biologic Therapy. In: Balch CM, Houghton AN, Soong S-J (eds), Cutaneous Melanoma, Philadelphia: J.B. Lippincott, 1998; 419-436.
7. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-α. Sem Oncol 1998; 25: 3-8.
8. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon-α therapy. Sem Oncol 1998; 25: 39-47.
9. Trask P, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18: 2316-2326.
10. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980.
11. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Fairclough DL, Cella DF. Functional assessment of cancer therapy (FACT-G): Non-response to individual questions. Qual Life Res 1996; 5: 321-329.
13. Hatcher L. A Step-by-Step Approach to Using the SAS System for Factor Analysis and Structural Equation Modeling. Cary, NC: SAS Institute Inc., 1994; 588 pp.
14. Cattell RB. The meaning and strategic use of factor analysis. In: Cattell RB (ed.), Handbook of Multivariate Experimental Psychology, Chicago, Rand-McNally, 1966.
15. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334.
16. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley and Sons, Inc., 1973; 67-74.
17. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis. Upper Saddle River, New Jersey: Prentice-Hall, Inc., 1992; 219-284.
18. Schlucter MD. Methods for the analysis of informatively censored longitudinal data. Statist Med 1992; 11: 1861-1870.
19. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic significance of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
20. Cattell RB. The screen test for the number of factors. Multivar Behav Res 1966; 1: 245-276.
21. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109-112.
22. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 1998; 159: 1988-1992.
23. Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Qual Life Res 1996; 5(3): 1-12.
24. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74.